Jim Boonyaratanakornkit
Infectious Disease · Seattle, WANPI 1356630222
Payments from drug & device makers
What this record shows
This record is dominated by grants: $60,000 of the $62,196 with a category attached, or 96.5%. Sanofi accounts for 96.5% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $30,000 and has fallen 92.7% since, to $2,196 in 2025. Among infectious disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $10,366 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$60K
- AstraZeneca$2K
Across 62 payments — averaging $22,670 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$863K
- AstraZeneca$492K
- Regeneron$50K
What the payments were for
- Consulting fees$1,5933%
- Grants$60,00096%
- Travel & lodging$5851%
- Food & beverage$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $60,000 |
| AstraZeneca | 4 | $2,196 |
How this compares
$62,196 in reported general payments places this provider in the 95th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Seattle
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Anna WaldSeattle$103K
- Michael BoeckhSeattle$59K
- Jason GoldmanSeattle$58K
- Connie CelumSeattle$57K
- Hyang KimSeattle$51K
- Ferric FangSeattle$49K
- Heidi CraneSeattle$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.